Physician

Michael A Collins, D.O.

According to 2025 Medicare claims, Michael Collins, D.O. (NPI: 1770593063) practices nephrology in the Huntington-Ashland, WV-KY-OH market, with the plurality of this provider's patient population coming from Cabell, WV. This provider's primary affiliated billing organization is ST. MARY'S HIMG, LLC (NPI: 1184233454; TIN: 85-2017234) and primary practice location at 25702-1241. Collins is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Collins' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,027 traditional Medicare patients, billed 3,945 HCPCS/CPT codes, and received $256,836 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 7,929 prescription claims across 1,207 beneficiaries totaling $562,651 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 12 claims. Open Payments data shows 97 records totaling $1,525. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $428,794 to $256,836. Concurrently, Part D prescription costs have changed little. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,050 and ending at $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,119	23,522	$428,794
2016	1,249	40,537	$515,348
2017	1,265	66,553	$511,932
2018	1,296	44,713	$489,307
2019	1,418	50,761	$556,080
2020	1,273	23,717	$429,080
2021	1,132	4,441	$294,803
2022	1,122	4,351	$273,213
2023	1,063	4,046	$247,124
2024	1,027	3,945	$256,836

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	696	5,572	$500,519
2016	734	6,163	$709,625
2017	835	7,018	$607,312
2018	849	7,767	$465,830
2019	978	7,687	$522,864
2020	974	7,800	$530,752
2021	938	6,808	$652,834
2022	946	6,630	$701,454
2023	1,042	7,341	$593,484
2024	1,207	7,929	$562,651

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	219	$16,990
2017	N/R	47	$10,905
2018	N/R	138	$18,880
2019	N/R	163	$28,640
2020	N/R	112	$14,049
2021	N/R	329	$146,874
2022	N/R	226	$117,979
2023	N/R	N/R	N/R
2024	N/R	12	$176

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	148	186	$138
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	144	144	$98
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	158	660	$63
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	830	1,653	$47
99231	Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes	156	757	$39

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	49	2,370	$196,146
Jardiance	Empagliflozin	61	2,910	$56,722
Farxiga	Dapagliflozin Propanediol	54	2,520	$48,395
Renvela	Sevelamer Carbonate	13	570	$34,594
Eliquis	Apixaban	12	960	$18,475

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$176

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	97	$1,525	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Michael A. Collins, D.O.?

Tedicare shows public-source Medicare data for Michael A. Collins, D.O. (NPI 1770593063), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Michael A. Collins, D.O. have ACO affiliation data?

Michael A. Collins, D.O. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Michael A. Collins, D.O.?

Michael A. Collins, D.O. is linked to ST. MARY'S HIMG, LLC (billing NPI 1184233454) in the available physician profile data.

Does Michael A. Collins, D.O. have Open Payments data?

Michael A. Collins, D.O. has 97 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.